ArticleJournal of thoracic disease2025
Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unraveling the multidimensional pleural ecosystem of lung cancer-associated malignant pleural effusion.Cancer cell international · 2026Review
- Development and multicenter validation of a predictive model for malignant pleural effusion recurrence.iScience · 2026Article
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant pleural effusion (MPE) is a common metastatic site in non-small cell lung cancer (NSCLC) and is associated with poor prognosis. However, data on MPE in the context of immunotherapy are limited. This study aimed to evaluate the clinical outcomes of NSCLC patients with MPE undergoing immunotherapy. Methods: This study included NSCLC patients treated with immune checkpoint inhibitors (ICIs) at Tianjin Medical University Cancer Institute & Hospital from January 2018 to August 2024. The presence of cytologically confirmed MPE was defined as the MPE group, against which the absence of pleural effusion was defined as the control group. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Results: A total of 167 NSCLC patients treated with ICIs were included, with 84 in the MPE group and 83 in the control group. There were statistically significant differences in PFS and OS between the MPE and control groups (both P<0.05). The median follow-up was 18 months. The median PFS in the MPE group was 9.50 months [95% confidence interval (CI): 7.08-11.92], while in the control group, the median PFS was 16.50 months (95% CI: 8.74-24.26). The median OS in the MPE group was 20.0 months (95% CI: 15.61-24.39), while in the control group, the median OS was 32.0 months (95% CI: 18.11-45.89). Conclusions: MPE remains an independent risk factor for poor prognosis in NSCLC even after immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.